Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma

• Published in: Expert opinion on emerging drugs Vol. 28; no. 1; p. 17
• Main Authors: Jain, Rohit K, Singh, Avani M, Wang, Xuefeng, Guevara-Patiño, José A, Sonpavde, Guru
• Format: Journal Article
• Language: English
• Published: England 02.01.2023
• Subjects: Antibodies, Monoclonal - adverse effects; Carcinoma, Transitional Cell - drug therapy; Humans; Immunoconjugates - therapeutic use; Immunotherapy; Urinary Bladder Neoplasms - drug therapy; KIR-2; urothelial carcinoma; FGFR; HER-2; VEG-F; Monoclonal antibody therapy
• ISSN: 1744-7623
• DOI: 10.1080/14728214.2023.2186398

The treatment landscape for advanced-stage, unresectable or metastatic urothelial carcinoma (mUC) has shifted dramatically over a short period of time, with new therapeutic agents available for clinical use. However, despite these recent advances in the field, mUC continues to be a disease with significant morbidity and mortality and remains generally incurable. While platinum-based therapy remains the backbone of therapy, many patients are ineligible for chemotherapy or have failed initial chemotherapy treatment. In post-platinum treated patients, immunotherapy and antibody drug conjugates have provided incremental advances, but agents with better therapeutic index guided by precision medicine are needed. This article covers the available monoclonal antibody therapies in mUC excluding immunotherapy and antibody drug conjugates. Included are a review of data utilizing monoclonal antibodies targeting VEG-F, HER-2, FGFR, and KIR-2 in the setting of mUC. A literature search from 6/2022- 9/2022 was performed utilizing PubMed with key terms including urothelial carcinoma, monoclonal antibody, VEG-F, HER-2, FGFR. Often used in combination with immunotherapy or other therapeutic agents, monoclonal antibody therapies have exhibited efficacy in mUC in early trials. Upcoming clinical trials will further explore their full clinical utility in treating mUC patients.